Cosylab and Heron Neutron Medical Corp. Sign Letter of Intent to Advance Global Deployment of Accelerator-Based BNCT Systems
AI-summarised brief · reviewed before publication
Cosylab and Heron Neutron Medical Corp. have signed a Letter of Intent to advance the global deployment of Accelerator-Based Boron Neutron Capture Therapy (AB-BNCT) systems. The collaboration aims to accelerate the development and integration of sophisticated software solutions for AB-BNCT while strengthening its international market access and business development. By combining Cosylab's expertise in mission-critical software and complex system integration with Heron's end-to-end BNCT platforms, the partnership aims to drive broader global clinical adoption of this highly targeted cancer treatment modality. The partnership is expected to accelerate market readiness and clinical adoption of AB-BNCT.